SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| KOSTER CHRISTOPHER | Secretary & General Counsel | 2026-08-26 | Open-market sell | 56500 | $3.8M |
| KOSTER CHRISTOPHER | Secretary & General Counsel | 2026-08-18 | Open-market sell | 47603 | $3.1M |
| DIAZ PAUL J | Director | 2026-07-28 | Grant/award | 2771 | $0 |
| Tyler Lauren M | Director | 2026-07-17 | Grant/award | 3155 | $0 |
| COUGHLIN CHRISTOPHER J | Director | 2026-06-30 | Grant/award | 562 | $0 |
| EPPINGER FREDERICK H | Director | 2026-06-30 | Grant/award | 833 | $0 |
| Samuels Theodore R. II | Director | 2026-06-30 | Grant/award | 465 | $0 |
| TANJI KENNETH | Director | 2026-06-30 | Grant/award | 581 | $0 |
| Tyler Lauren M | Director | 2026-06-30 | Grant/award | 61 | $0 |
| SMITH SUSAN RAYE | Chief Operating Officer | 2026-06-15 | Tax withholding | 483 | $31K |
| Burdick Kenneth A | Director | 2026-06-10 | Open-market sell | 80000 | $5.2M |
| BLUME JESSICA L. | Director | 2026-05-12 | Grant/award | 3992 | $0 |
| Burdick Kenneth A | Director | 2026-05-12 | Grant/award | 3992 | $0 |
| COUGHLIN CHRISTOPHER J | Director | 2026-05-12 | Grant/award | 3992 | $0 |
| Dallas H James | Director | 2026-05-12 | Grant/award | 3992 | $0 |
| EPPINGER FREDERICK H | Director | 2026-05-12 | Grant/award | 6654 | $0 |
| FORD MONTE E | Director | 2026-05-12 | Grant/award | 3992 | $0 |
| Samuels Theodore R. II | Director | 2026-05-12 | Grant/award | 3992 | $0 |
| TANJI KENNETH | Director | 2026-05-12 | Grant/award | 3992 | $0 |
| MCNALLY TANYA M | Chief People Officer | 2026-04-15 | Tax withholding | 964 | $36K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
A $6.7 billion goodwill impairment charge, pervasive regulatory headwinds across Medicaid and Marketplace, and concrete Medicaid contract losses in Texas and Georgia define a materially deteriorated risk profile. Regulatory changes — CMS waiver halts, OBBBA work requirements, Enhanced APTC expiration, and a new MCO tax equalization mandate with no premium offset mechanism — are compounding membership attrition and profitability pressure simultaneously. The two easing items (debt reduction and one removed tax-credit risk) are insufficient to offset the breadth and severity of worsening across impairment, regulatory, and competitive themes.
9 company-specific · 2 eased/removed · 2 common-mode
Company disclosed a $6.7 billion goodwill impairment charge in Q3 2025 due to market conditions and stock price decline, materially worsening the risk profile.
An impairment charge with respect to our recorded goodwill, intangible assets and real estate portfolio could have a material impact on our results of operations and shareholders' equity . Changes in…
Risk escalated materially: new specific 2025 examples of higher-than-expected morbidity, Medicaid medical costs, and behavioral health expenses; added language on rate adjustment delays and premium deficiency reserves.
Risks Relating to Our Business Failure to timely and effectively identify and mitigate medical cost trends and receive adequate rate adjustments to account for increased acuity could have a material…
Added specific 2025 negative risk adjustment charge, timing delays in rate-setting data, tariff cost pressures, and 2026 refiling uncertainty. Escalates from generic pricing risk to concrete financial impact.
Any failure to adequately and timely price or anticipate demand for products offered, anticipate changes to the competitive landscape or any reduction in products offered for Medicare and in the…
New disclosure of specific, imminent tax risk: CMS guidance (Nov 2025) requiring states to equalize Medicaid MCO and commercial insurance tax rates by end of 2026. Company cannot offset resulting tax increases via premium adjustments on already-approved 2025 Marketplace rates, creating material profitability pressure.
We might be adversely impacted by tax legislation or challenges to our tax positions. We are subject to the tax laws in the U.S. at the federal, state and local government levels and to the tax laws…
Company now explicitly discloses active protests of Texas and Georgia Medicaid reprocurements where it lost bids—concrete contract losses replacing generic TRICARE example.
If we are not successful in procuring new government contracts or renewing existing government contracts, or if we receive an adverse finding or review resulting from an audit or investigation, our…
Risk-sharing program design now explicitly flagged as material risk factor. IRA impact shifted from "expected to" to "has substantially increased" risk exposure, signaling realized rather than prospective harm.
We derive a portion of our cash flow and gross margin from our PDP operations, for which we submit annual bids for participation. The results of our bids and the design of the risk-sharing program…
Shift from specific 2025 California reprocurement example to current active protests in Texas and Georgia, indicating material loss of Medicaid contracts and ongoing disputes.
We derive a significant portion of our premium revenues from operations in a number of states, and our results of operations, financial condition or cash flows could be materially adversely affected…
Company removed its 85% Star rating goal for 2026 and added explicit statement that rates are insufficient for medical cost trends, escalating regulatory and pricing risk.
Our Medicare programs are subject to a variety of unique risks that could adversely impact our financial results. If we fail to design and maintain programs that are attractive to Medicare…
Removed specific HNL substance abuse reimbursement dispute example; added explicit penalties/sanctions/damages language for directory accuracy non-compliance, escalating regulatory consequences.
If we are unable to maintain relationships with our provider networks and timely update our provider directories, our profitability may be materially adversely affected. Our profitability depends, in…
Removal of material regulatory risk tied to enhanced tax credit expiration (Dec 2025). Suggests credit renewed, extended, or risk otherwise resolved.
Risks Relating to Regulatory and Legal Matters If eligibility for the enhanced advance premium tax credit for Marketplace members expires without renewal or the eligibility for the credit is modified…
Debt decreased $1.1B (6% reduction). Covenant metrics simplified from dual ratios to single debt-to-capital ratio, potentially easing compliance burden and financial flexibility constraints.
We have substantial indebtedness outstanding and may incur additional indebtedness in the future. Such indebtedness could reduce our agility and may adversely affect our financial condition. As of…
Multiple new regulatory changes disclosed: CMS halting Section 1115 waivers, OBBBA work requirements reducing Medicaid eligibility, Enhanced APTC expiration, Final Rule tightening Marketplace integrity. Combined effect expected to reduce membership and increase morbidity.
Significant changes to the ACA and the other government-sponsored healthcare programs in which we participate could materially and adversely affect our results of operations, financial condition, and…
New specific regulatory risks disclosed: Final Rule (June 2025) repealing SEP for <150% FPL, OBBBA restrictions on APTC and income verification, New York Essentials Plan-5 termination by July 2026, and anticipated Medicaid Expansion morbidity increases. These represent material new regulatory headwinds.
Risks Relating to Regulatory and Legal Matters Reductions or delays in funding of, changes to eligibility requirements for, government-sponsored healthcare programs in which we participate, and any…
Centene announced a partial redemption of $500 million of its 4.25% Notes due 2027, which constitutes a material modification of existing debt obligations. While technically a redemption rather than a new issuance, this represents a significant direct financial obligation event affecting the company's capital structure and debt profile. The redemption price of 100% of principal plus accrued interest is a material financial transaction that would affect investor assessment of the company's liquidity and debt management.
View raw filing on EDGAR →Centene Corporation issued a press release on July 28, 2026, announcing second quarter 2026 financial results, including GAAP diluted EPS of $2.19, adjusted diluted EPS of $2.51, and increased full-year 2026 guidance (GAAP diluted EPS greater than $3.11 and adjusted diluted EPS greater than $4.80), with comprehensive financial metrics and segment performance.
View raw filing on EDGAR →The Board elected Paul Diaz as a director effective July 28, 2026, to fill the vacancy created by Kenneth Burdick's resignation, and assigned him to the Audit Committee and Quality and Compliance Committee. Diaz brings substantial healthcare executive experience as former CEO of Myriad Genetics and Kindred Healthcare.
View raw filing on EDGAR →Lauren M. Tyler was elected to Centene's Board of Directors effective June 19, 2026, filling a newly created vacancy as the Board expanded from 9 to 10 members. She was assigned to the Audit Committee and Compensation and Talent Committee, bringing 30+ years of leadership experience including senior roles at JPMorgan Chase and current board service at Cencora and Guardian Life.
View raw filing on EDGAR →